Audit/research project for follow-up cystoscopy superficial bladder cancer

	Prospectively registered
No longer recruiting	☐ Protocol
Overall study status	Statistical analysis plan
Completed	Results
Condition category	Individual participant data
Cancer	Record updated in last year
	Completed Condition category

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr R Hall

Contact details

Freeman Hospital Newcastle United Kingdom NE7 7DN

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers SUPBLACAN

Study information

Scientific Title

Audit/research project for follow-up cystoscopy superficial bladder cancer

Study objectives

- 1. To conduct an audit of a new programme of cystoscopic follow-up for patients with Ta. T1 bladder carcinoma.
- 2. To conduct a randomised comparison of:
- 2.1. Mitocytin-C versus epirubicin as single intravesical instillations at the time of diagnosis to evaluate relative efficacy in prevention of recurrent bladder cancer
- 2.2. A single instillation of intravesical chemotherapy (MMC or Epi) versus five instillations (to be given at the time of each follow-up cystoscopy for 1 year) to determine the relative efficacy in reducing tumour recurrence in medium risk Ta.T1 bladder cancer.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Cancer (neoplasms): Bladder (superficial)

Interventions

Not provided at time of registration

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Primary outcome measure

- 1.1 Number of unplanned incidents (return with symptoms, need for unscheduled cystoscopies or tumour resections).
- 1.2 Tumour recurrence rate and number of patients progressing to muscle invasion at 2 years. iii. Inter-hospital variation of type of cystoscopy, anaesthetic, out-patient, day case, in-patient mix and cost of same.
- 2. Recurrence rate and progression to muscle invasion at 2 years.

Secondary outcome measures

Not provided at time of registration

Overall study start date

16/05/1994

Completion date

15/05/1997

Eligibility

Key inclusion criteria

Not provided at time of registration

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

16/05/1994

Date of final enrolment

15/05/1997

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Freeman Hospital Newcastle United Kingdom NE7 7DN

Sponsor information

Organisation

NHS R&D Regional Programme Register - Department of Health (UK)

Sponsor details

The Department of Health Richmond House 79 Whitehall London United Kingdom SW1A 2NL +44 (0)20 7307 2622 dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

http://www.doh.gov.uk

Funder(s)

Funder type

Government

Funder Name

NHS Executive Northern and Yorkshire (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration